Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
Study Details
Study Description
Brief Summary
This study is to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors [AI] (test) versus dual-chamber syringes [DCS] (reference) under controlled conditions in healthy adult subjects.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Nemolizumab With Auto-Injector (AI) Participants will receive a 60-mg dose of nemolizumab as a 2 successive subcutaneous injections of 30 mg nemolizumab at either of the same location i.e., abdomen, front upper thigh, or outer upper arm and on the same side with injection sites at least 1 inch (2.5 cm) apart with Auto-Injector (AI). |
Drug: Nemolizumab
Nemolizumab with Auto-Injector (AI).
|
| Experimental: Nemolizumab With Dual Chamber Syringe (DCS) Participants will receive a 60-mg dose of nemolizumab as a 2 successive subcutaneous injections of 30 mg nemolizumab at either of the same location i.e., abdomen, front upper thigh, or outer upper arm and on the same side with injection sites at least 1 inch (2.5 cm) apart with Dual Chamber Syringe (DCS). |
Drug: Nemolizumab
Nemolizumab with Dual-Chamber Syringe (DCS).
|
Outcome Measures
Primary Outcome Measures
- Change in Observed Maximum Serum Concentration (Cmax) of Nemolizumab Administered With Auto-Injector (AI) [From Baseline up to Week 12]
- Change in Observed Maximum Serum Concentration (Cmax) of Nemolizumab Administered With Dual-Chamber Syringe (DCS) [From Baseline up to Week 12]
- Change in Area under Concentration-time Curve Extrapolated to Infinity (AUC 0-inf) of Nemolizumab Administered With AI (Auto-Injector) [From Baseline up to Week 12]
- Change in Area under Concentration-time Curve Extrapolated to Infinity (AUC 0-inf) of Nemolizumab Administered With Dual-Chamber Syringe (DCS) [From Baseline up to Week 12]
Secondary Outcome Measures
- Change in Area Under the Concentration-time Curve Over the Specified Interval (AUC 0-4 weeks) of Nemolizumab Administered With Auto-Injector (AI) [From Baseline up to Week 12]
- Change in Area Under Concentration-time Curve From Administration to the Last Observed Concentration Time t (AUC 0-last) of Nemolizumab Administered With Auto-Injector (AI) [From Baseline up to Week 12]
- Change in T max (Time to Achieve C max) of Nemolizumab Administered With Auto-Injector (AI) [From Baseline up to Week 12]
- Change in t 1/2 (Half-life) of Nemolizumab Administered With Auto-Injector (AI) [From Baseline up to Week 12]
- Change in Area Under the Concentration-Time Curve Over the Specified Interval (AUC 0-4 weeks) Nemolizumab Administered With Dual-Chamber Syringe (DCS) [From Baseline up to Week 12]
- Change in Area Under Concentration-time Curve From Administration to the Last Observed Concentration Time t (AUC 0-last) of Nemolizumab Administered With Dual-Chamber Syringe (DCS) [From Baseline up to Week 12]
- Change in T max (Time to Achieve C max) of Nemolizumab Administered With Dual-Chamber Syringe (DCS) [From Baseline up to Week 12]
- Change in t 1/2 (Half-life) of Nemolizumab When Administered With Dual-Chamber Syringe (DCS) [From Baseline up to Week 12]
- Assessment of the Immunogenicity (anti-drug antibodies, ADA) of Nemolizumab Administered With Auto-Injector (AI) [From Baseline up to Week 12]
- Assessment of the Immunogenicity (anti-drug antibodies, ADA) of Nemolizumab Administered With Dual-Chamber Syringe (DCS) [From Baseline up to Week 12]
- Number of participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) [From Baseline up to Week 12]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male and female participants aged 18 to 65 years at screening visit.
-
Body weight ≥ 45 kg and body mass index between ≥18.0 and <30.0 kg/m^2 at both screening and baseline visits.
-
Medically healthy with normal clinical status as judged by the investigator based on medical history, physical examination, and clinical laboratory tests.
-
Willing to abstain from all prescription medications during the study, (defined hereafter as after signing of informed consent form), except to treat AEs and contraception, and as permitted under Exclusion 2. Limited use of non-prescription medications/supplements that are not believed to affect subject's safety or the overall results of the study may be permitted at the discretion of investigator.
-
Female participants of childbearing potential (i.e., fertile, after menarche and, until becoming postmenopausal unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the study drug injection, or to use an adequate and approved method of contraception throughout the study and for 12 weeks after the study drug injection. Males are not required to use contraception, and there is no restriction on sperm donation.
-
Female participants of non-childbearing potential must meet one of these criteria; absence of menstrual bleeding for 1 year before the screening visit with no other medical reason, confirmed with follicle-stimulating hormone (FSH) level in the postmenopausal range or documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 3 months before the study.
-
Willing and able to comply with all of the time commitments and procedural requirements of the clinical study protocol.
-
Understand and sign and informed consent form before any investigational procedure(s) are performed.
Exclusion Criteria:
-
History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, e.g., monoclonal antibody) or to any of the study drug excipients.
-
Cutaneous infection within 1 week before the baseline visit or any infection requiring treatment with oral, parental antibodies, antivirals, antiparasitics, or antifungals within 2 weeks before the baseline visit.
-
Any confirmed or suspected coronavirus disease (COVID-19) infection within 2 weeks before screening or baseline visit.
-
Positive serology results (hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb], hepatitis C [HCV] antibody with positive HCV RNA, or human immunodeficiency virus [HIV] antibody) at the screening visit.
-
Known or suspected immunosuppression or unusually frequent, recurrent, severe, or prolonged infections as per investigator judgment.
-
History of lymphoproliferative disease or history of malignancy of any organ system within last 5 years, except for basal cell carcinoma, squamous cell carcinoma in situ (Bowen's disease), or carcinomas in situ of the cervix that have been treated and have no clinical evidence of recurrence in the last 12 weeks before baseline visit, or actinic keratoses that have been treated.
-
Previous treatment with Nemolizumab.
-
Known active or untreated latent tuberculosis infection.
-
Any condition that may interfere with study assessments (e.g., poor venous access or needle phobia).
-
Having received a live-attenuated or non-live vaccine within 4 weeks before the baseline visit or are expected to be vaccinated during the study or during the 12 weeks after the last study drug injection, except for non-live seasonal vaccinations, COVID-19 and /or emergency vaccinations.
-
Planned or expected major surgical procedure during the clinical study.
-
Pregnant women, breastfeeding women, or women planning a pregnancy during the study or 12 weeks after the study drug injection.
-
Participating or participated in any other study with an investigational drug or device within the past 8 weeks before the screening visit, or is in an exclusion period from a previous study.
-
Participants who have donated ≥ 500 mL of blood in the last 3 months before doing.
-
History of alcohol or substance abuse within 6 months of the screening visit.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Galderma Investigational Site 7024 | Tempe | Arizona | United States | 85283 |
| 2 | Galderma Investigational Site 7023 | Lincoln | Nebraska | United States | 68502 |
Sponsors and Collaborators
- Galderma R&D
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RD.06.SPR.201590